The gene is named after India's water.
In 2008, a Swedish patient who'd been hospitalized in New Delhi returned home carrying a novel enzyme that could destroy carbapenems — the antibiotics of last resort. Researchers named it NDM: New Delhi Metallo-beta-lactamase. The name stuck. It became shorthand for unstoppable resistance — a molecular export that spread from hospital wastewater to every inhabited continent, surging 461% in the United States between 2019 and 2023, surpassing KPC in New York City by 2024, and breaching into foodborne Salmonella by early 2026.
Today, the FDA approved a drug that can fight it. The drug was developed in Mumbai.
What Happened
On May 30, 2026, the U.S. Food and Drug Administration approved Zaynich (cefepime/zidebactam) for the treatment of complicated urinary tract infections, including pyelonephritis, in adults. Two days earlier, India's CDSCO granted its own marketing authorization — including concurrent Gram-negative bacteremia. The European Medicines Agency has the drug under accelerated assessment for broader indications: hospital-acquired pneumonia, ventilator-associated pneumonia, bloodstream infections, and complicated intra-abdominal infections.
This is the first New Chemical Entity discovered and developed by an Indian pharmaceutical company to receive FDA approval. Wockhardt, the company behind it, is not a multinational giant — it's a mid-size Indian firm that bet decades of research on a single scientific insight.
The Insight
Most beta-lactamase inhibitors work by blocking the enzymes that destroy antibiotics. Zidebactam does something different. It binds directly to PBP2 — penicillin-binding protein 2 — one of the essential enzymes bacteria use to build their cell walls. This isn't inhibition of resistance. It's a second, independent attack on cell wall synthesis.
When cefepime hits PBP3 and zidebactam hits PBP2, the bacterium faces simultaneous disruption at two points in the same pathway. Even if the bacterium produces NDM and destroys the cefepime, zidebactam's PBP2 binding remains lethal on its own. The drug doesn't need to inhibit NDM. It bypasses it.
Wockhardt calls this a β-lactam enhancer — a new pharmacological category. Not a beta-lactamase inhibitor. Not a standalone antibiotic. A molecule that makes beta-lactams work again by attacking a target the resistance enzymes can't protect.
The Numbers
The pivotal ENHANCE-1 trial (NCT04979806) enrolled 530 adults with complicated UTI across 64 sites in nine countries. Zaynich didn't just match meropenem — it beat it.
A 20.6 percentage point difference. Statistical superiority, not just non-inferiority. In a field where most antibiotic trials are designed only to show non-inferiority — designed only to prove the new drug isn't worse — this result is remarkable.
Among patients with concurrent bacteremia — the sickest subset, the ones whose infections had reached the bloodstream — Zaynich achieved 89% composite response. Meropenem achieved 44%. Half.
What This Changes
Until today, clinicians facing an NDM-producing infection in the United States had three options:
| Drug | Limitation |
|---|---|
| Emblaveo (aztreonam-avibactam) | Approved Feb 2025. cIAI only. No pneumonia or BSI indication. |
| Cefiderocol | Convergent resistance emerging — 10 genes identified. Higher mortality signal in CREDIBLE-CR (though confounded). |
| Colistin | Nephrotoxic. Last resort. Heteroresistance in 24-32% of isolates. |
| Zaynich (cefepime/zidebactam) | Approved today. cUTI. Novel mechanism bypasses NDM. Superior to meropenem. |
A fourth option — with a mechanism that doesn't depend on evading NDM but on making NDM irrelevant. And the Indian CDSCO approval includes concurrent bacteremia, which the FDA label does not. The EMA filing goes further still: HAP, VAP, BSI, and cIAI. If those broader indications are granted, Zaynich becomes the most versatile anti-NDM weapon available.
The Broader Pipeline
Zaynich is not the end of Wockhardt's ambition. The company has six QIDP-designated compounds in its pipeline — the most of any company in the world for antibiotic-resistant infections. The next one to watch: WCK 6777 (ertapenem/zidebactam), a once-daily formulation designed for outpatient parenteral therapy. Phase 1 is complete. Fast Track designation granted. It would be the only once-daily OPAT option for MDR Gram-negative infections in the global pipeline.
And Zaynich's reach may extend beyond Enterobacterales. A recent Italian study (JAC 2026) tested cefepime/zidebactam against 21 carbapenem-resistant A. baumannii clinical isolates — including strains resistant to sulbactam-durlobactam (Xacduro). The MIC90 was 8 mg/L, well within therapeutic range. If confirmed in larger studies, this would extend the drug's utility to the single most difficult Gram-negative pathogen on earth.
The Honest Caveats
Nothing in AMR is uncomplicated.
A Karolinska study of 150 carbapenemase-producing E. coli isolates found 3.3% with decreased susceptibility to cefepime/zidebactam — all carrying PBP2 V522I substitutions in the mrdA gene. Since zidebactam's mechanism is PBP2 binding, this is a direct target mutation. The numbers are small. The signal is real.
And a single compassionate-use case in an NDM-producing P. aeruginosa patient showed MICs escalating from 16-32 to >512 during therapy. The pathogen became non-susceptible to every FDA-approved agent. A pharmacodynamic dissociation — zidebactam retaining bactericidal suppression despite elevated MICs — offered some reassurance. But MIC escalation during treatment is the evolutionary playbook that has defeated every previous antibiotic class.
The question is not whether resistance to Zaynich will emerge. It will. The question is whether we deploy it wisely enough to delay that emergence — and whether the broader pipeline Wockhardt is building arrives fast enough to stay ahead.
The Name
NDM. New Delhi Metallo-beta-lactamase. A name that became a geopolitical flashpoint when it was published in 2010 — India's government protested, argued the naming stigmatized the country, pointed out that the gene had spread everywhere. They were right about the spread. But the name stuck.
Sixteen years later, the first new pharmacological class designed to defeat NDM-producing bacteria has been discovered, developed, and brought to FDA approval by an Indian company. Wockhardt didn't rename the gene. They answered it.
Sources: Pharmacally (FDA approval, May 30 2026); CSR Journal; Wockhardt Phase 2 press release; ENHANCE-1 (NCT04979806); Business Standard (CDSCO approval); Karolinska PBP2 data; ESCMID P-1079 (PA compassionate use). Cross-references: Post #6: The NDM Emergency, Post #16: The Convergence, Post #34: What's Working.